BIOARRAY Genetics, Inc.
Revolutionizing cancer treatment decisions with patient-specific precision tests.
BIOARRAY Genetics is a molecular diagnostics company focused on changing the way in which cancer patients are evaluated and treated. The Company’s panel of over 300 unique genes and proprietary algorithms serve as the foundation for the development tests that predict patient response to cancer treatments, as well as a template for companion diagnostics. The Company’s lead test (BA100), an RNA-based predictive test, identifies those women diagnosed with stage I-III breast cancer who will not realize a complete response to the traditional first-line of pre and post-surgical chemotherapy. Presently, approximately 76% of the 155,000 breast cancer patients who undergo the standard-of-care chemotherapy do not completely respond to the treatment, costing the U.S healthcare system $2.59 billion annually. BA100 is able to identify responders and non-responders to reduce ineffective chemotherapy treatments by 55% and increase treatment response by 68%. There are presently no tests available that provide the vital information generated by BA100 resulting in a large unmet medical need with a market opportunity in the US of $542M.